Abstract:Abstract Current approaches for colorectal cancer (CRC) chemoprevention, including the use of NSAID, have tended predominantly toward modulating tumorigenic pathways rather than eliminating large number of premalignant or subclinical malignant cells. This tendency reflects the effort to keep toxicity to a minimum. The effectiveness of such modulative agents, however, is generally low to moderate, and long-term treatment is often required to produce any significant preventive benefit. In turn, long-term therapy frequently produces unanticipated adverse effects even with agents generally thought to have low toxicity. To overcome the challenges in current chemoprevention, we propose to perform chemoprevention in a therapy-like fashion, i.e., through short-term and intermittent treatments. The concept underlying this approach is based on elimination of large number of premalignant cells (to a greater degree than sought generally in chemoprevention) via short-tem treatments by specifically targeting genetic or epigenetic changes in premalignant cells. Periodically reducing or eliminating the number of premalignant cells through a series of noncontinuous/intermittent short-term therapies potentially will significantly reduce the chance of accumulation multiple mutations in same cells, which is required to generate malignant clones. This will delay or even completely prevent cancer in long-term. In this way, the potential side effects and costs often associated with long-term treatment could be minimized and controlled. In a recent paper (Nature. 2010 Apr 15; 464(7291): 1058-61. Epub 2010 Mar 28), we reported the development of a novel therapy-like chemoprevention procedure for CRC. This procedure is based on our finding that a deficiency in the adenomatous polyposis coli (APC) gene and subsequent activation of β-catenin lead to the repression of cellular caspase-8 inhibitor cFLIP expression through activation of c-Myc, and that all-transretinyl acetate (RAc) independently upregulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptors and represses decoy receptors. Thus, the combination of TRAIL and RAc induces apoptosis in APC-deficient premalignant cells without affecting normal cells in vitro. In addition, we demonstrate that short-term and noncontinuous TRAIL and RAc treatment induces apoptosis specifically in intestinal polyps, strongly inhibits tumor growth, and promotes survival in ApcMin mice. We further show that TRAIL and RAc induce significant cell death in human colon polyps in organ culture in vitro, providing a potentially selective therapeutic approach for CRC chemoprevention by targeting APC-deficient cells for apoptosis. This study demonstrated the feasibility, efficacy, and potential tolerability of therapy-like chemoprevention in an in vivo preclinical setting. Progress toward a clinical trial will be discussed. Citation Information: Cancer Prev Res 2010;3(12 Suppl):CN13-05.

Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis

Abstract B81: Colorectal Cancer Chemoprevention by Targeting APC-deficient Cells for Apoptosis

Abstract CN13-05: A Novel Approach for Colorectal Cancer Chemoprevention by Targeting APC-deficient Cells for Apoptosis

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Effects of Different Chemotherapeutic Agents on Reversing the Acquired Resistance to TRAIL Gene in DLD1 Colon Cancer Cells

Enhanced Anti-Tumor Activity by the Combination of TRAIL/Apo-2L and Combretastatin A-4 Against Human Colon Cancer Cells Via Induction of Apoptosis in Vitro and in Vivo.

A Small Natural Molecule CADPE Kills Residual Colorectal Cancer Cells by Inhibiting Key Transcription Factors and Translation Initiation Factors

[Action of Apoptosis-Induced Ligand Gene in Relation to Tumor Necrosis Factor on Human Colon Cancer Cell Line HT29].

Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer

Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC

Apple Polysaccharides Induce Apoptosis in Colorectal Cancer Cells.

Adenomatous polyposis coli in cancer and therapeutic implications

Effects of ABL silencing combined with TRAIL and DOX on apoptosis of colorectal cancer HT29 cells

TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression

Ex vivo explant model of adenoma and colorectal cancer to explore mechanisms of action and patient response to cancer prevention therapies

BAY61-3606 Potentiates the Anti-Tumor Effects of TRAIL Against Colon Cancer Through Up-Regulating DR4 and Down-Regulating NF-κB.

Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway

Agrocybe cylindracea fucoglucogalactan induced lysosome-mediated apoptosis of colorectal cancer cell through H3K27ac-regulated cathepsin D

Apple Polysaccharide Reduces Nf-Kb Mediated Colitis-Associated Colon Carcinogenesis

Mechanism of APC truncation involved in colorectal cancer tumorigenesis (Review)

Combination of long-acting TRAIL and tumor cell-targeted photodynamic therapy as a novel strategy to overcome chemotherapeutic multidrug resistance and TRAIL resistance of colorectal cancer